Journal profile · Pharmacology & Pharmacy
Expert Opinion on Investigational Drugs
ISSN 1354-3784 · eISSN 1744-7658 · Taylor and Francis Ltd. · ENGLAND · Monthly · Founded 1994
Expert Opinion on Investigational Drugs: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.39; hybrid open access; median 117 days to acceptance (98 articles, last 24 months); community-reported acceptance: moderate; 86 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion on Investigational Drugs is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Monoclonal and Polyclonal Antibodies Research, Diabetes Treatment and Management and Asthma and respiratory diseases, together about 16.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Monoclonal and Polyclonal Antibodies ResearchMedicine5.7%
- Diabetes Treatment and ManagementMedicine5.5%
- Asthma and respiratory diseasesMedicine5.2%
- Lipoproteins and Cardiovascular HealthMedicine4.7%
- HIV/AIDS drug development and treatmentMedicine4.6%
- HER2/EGFR in Cancer ResearchMedicine4.6%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience4.5%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.39LetPub ·
- CiteScore 2026-06
- 8.5LetPub ·
- SJR 2026-06
- 1.2LetPub ·
- SNIP 2026-06
- 0.84LetPub ·
- h-index
- 94LetPub ·
- h-index
- 133OpenAlex ·
- i10-index
- 2,929OpenAlex ·
- 2-year mean citedness
- 4.77OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 5.47%LetPub ·
Volume
- Articles per year
- 73LetPub ·
Articles by year OpenAlex count · 5,099 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 66 | 30 | 25 |
| 2025 | 86 | 26 | 362 |
| 2024 | 110 | 29 | 863 |
| 2023 | 109 | 32 | 1,491 |
| 2022 | 85 | 27 | 1,392 |
| 2021 | 111 | 35 | 2,864 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
117 daysMedian, submission to acceptance · P25–P75 79 days – 158 days
- Acceptance to online
- median 10 days (98 articles)
- Submission to online
- median 129 days
- Sample
- 98 articles with submission and acceptance dates (169 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1994
- ISSN
- 1354-3784
- Electronic ISSN
- 1744-7658
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Opinion on Investigational Drugs
What CAS zone is Expert Opinion on Investigational Drugs in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion on Investigational Drugs is in Zone 3 of Medicine, and in Zone 2 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion on Investigational Drugs?
The latest impact factor listed by LetPub is 4.39; CiteScore 8.5, h-index 133.
How long does peer review take at Expert Opinion on Investigational Drugs?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 117 days (interquartile range 79–158 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Opinion on Investigational Drugs?
According to LetPub and DOAJ records, Expert Opinion on Investigational Drugs is indexed in SCIE and Scopus.
Is Expert Opinion on Investigational Drugs open access, and what is the APC?
Expert Opinion on Investigational Drugs is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .